SLGL Overview

Sol-Gel Technologies Ltd is a clinical-stage dermatology company. The Company is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The Company is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Wall Street analysts forecast SLGL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLGL is50.00 USD with a low forecast of 50.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Sol Gel Technologies Ltd revenue for the last quarter amounts to 108.00K USD, decreased -89.52

Sol Gel Technologies Ltd. EPS for the last quarter amounts to -1.31 USD, decreased -95.86

Sol Gel Technologies Ltd (SLGL) has 28 emplpoyees as of May 31 2026.

Today SLGL has the market capitalization of 241.45M USD.